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Accumulating evidence suggests that alloreactive memory T cells (Tm) may form a barrier to
tolerance induction in large animals and humans due in part to a resistance to suppression
by Treg. However, why Tm are resistant to regulation and how the Tm response to an
allograft differs from that of naı ¨ve T cells, which are amenable to suppression by Treg,
remains unknown. Here, we show that accelerated graft rejection mediated by CD8
1 Tm was
due to the enhanced recruitment of PMN to allografts in a mouse skin allograft model.
Importantly, depletion of PMN slowed the kinetics of (but did not prevent) rejection mediated
by Tm and created a window of opportunity that allowed subsequent suppression of
rejection by Treg. Taken together, we conclude that CD8
1 Tm are not intrinsically resistant to
suppression by Treg but may rapidly inﬂict substantial graft damage before the establish-
ment of regulatory mechanisms. These data suggest that if Tm responses can be attenuated
transiently following transplantation, Treg may be able to maintain tolerance through the
suppression of both memory and naı ¨ve alloreactive T-cell responses in the long term.
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Introduction
Immunological memory is one of the hallmarks of the adaptive
immune response that is instrumental in the ﬁght against infection,
allowing rapid and efﬁcient clearance of a previously encountered
antigen following secondary exposure. However, in the setting of
transplantation, there is now convincing evidence that memory
T cells (Tm) may also contribute to the rejection of allogeneic organ
transplants. For example, in clinical transplantation, alloreactive
Tm have been shown to participate in both acute and chronic
rejection processes in heart, kidney and liver transplant recipients
[1–5]. Importantly, Heeger et al. have provided evidence that the
presence of alloreactive Tm, pre-transplant, is linked to an increase
in the incidence and severity of acute rejection episodes [6]. Tm
have also been found to be resistant to leukocyte depleting agents,
such as Alemtuzumab (Campath-1H), that are increasingly being
used as induction therapy in transplant recipients [7, 8].
In addition to clinical evidence suggesting that alloreactive
Tm contribute to allograft rejection, there are a number of reports
demonstrating that alloreactive Tm may be detrimental to toler-
ance induction in experimental models [9–13]. For example,
Adams et al. have shown that CD8
1 Tm generated following virus
infection can exhibit cross-reactivity to alloantigens and cause
rejection of skin grafts in recipients treated with a tolerance
inducing protocol [13]. We have previously shown that the
perturbation in tolerance induction caused by alloreactive Tm
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suppression mediated by Treg [9].
Despite a plethora of evidence supporting a role for Tm in
transplant rejection and the ﬁnding that Tm form a barrier to
tolerance induction, the exact differences between naı ¨ve and Tm-
mediated rejection responses have yet to be elucidated. This may
be explained in part through the difﬁculty associated with truly
comparing a naı ¨ve and Tm response to an allograft, as naı ¨ve and
Tm populations are likely to harbour different precursor
frequencies of alloreactive T cells that may be clonally distinct,
with alloreactive naı ¨ve and Tm having a different range of afﬁ-
nities/avidities and speciﬁcities for alloantigen, all of which may
alter the observed alloresponse.
To obviate these potential problems in this study we used
alloreactive CD8
1 TCR-transgenic T cells (BM3) to characterise
naı ¨ve and Tm responses to a skin allograft where the naı ¨ve and Tm
existed at the same frequency and have the same afﬁnity and
speciﬁcity for alloantigen (H2K
b). Using such a model, we demon-
strate that BM3 Tm reject skin allografts more aggressively than
their naı ¨ve counterparts due to the rapid recruitment of poly-
morphonuclear cells (PMN) to the graft. Furthermore, we show that
the removal of PMN not only attenuates Tm-mediated rejection but
allows donor-reactive Treg to suppress memory BM3 T cells in a
manner similar to that seen during control of naı ¨ve responses.
Results
H2K
b-reactive BM3 Tm mediate accelerated rejection of
H2K
b1 skin grafts
Alloreactive Tm can be characterised by their ability to elicit a rapid
and potent recall response on re-exposure to alloantigen [10, 11,
1 3 – 1 5 ] .F i r s t ,w es o u g h tt oe x a m i n ew h e t h e rC D 8
1CD44
1 BM3 Tm
exhibited such properties and were able to reject skin allografts at a
faster tempo than naı ¨ve BM3 T cells. To this end, CBARAG
/ mice
received 110
5 naı ¨ve or memory BM3 T cells i.v. before being
transplanted with an H2K
b1 skin graft the day after cell transfer. We
found that BM3 Tm were able to mediate rejection of H2K
b1 skin
grafts signiﬁcantly faster than naı ¨ve BM3 T cells (Fig. 1; median
survival time516 days and 26 days, respectively; p50.01).
Naı ¨ve and memory BM3 T cells undergo similar
priming to skin allografts
Next, the mechanisms underlying the ability of CD8
1 BM3 Tm to
facilitate accelerated allograft rejection were examined. 110
5
CFSE labelled naı ¨ve or memory BM3 T cells were transferred to
CBARAG
/ mice that received an H2K
b1 skin graft 1 day later.
Live BM3 T cells were analysed as shown in Supporting Information
Fig. 1. By 5 days post-transplantation, both naı ¨ve and memory BM3
T cells were found to have proliferated in the DLN but not
contralateral lymph nodes (CLN), mesenteric lymph nodes or
spleen (Fig. 2A–C; data not shown). Further analysis revealed that
both naı ¨ve and memory BM3 T cells in the DLN had undergone
similar levels of proliferation as there was no difference in the rate
of division between Tm and naı ¨ve BM3 T cells in response to the
H2K
b1 graft (Fig. 2B). Indeed, analysis of the percentage of cells
that had passed through three or more divisions revealed a
signiﬁcant increase in the percentage of proliferating cells in the
DLN compared to the CLN but no signiﬁcant difference between Tm
(62.9731 %) and naı ¨ve (79720.9%) BM3 T cells (Fig. 2C).
By 10 days after allogeneic skin grafting, the vast majority of
BM3 T cells from mice that had received memory (63.479.4%)
or naı ¨ve BM3 T cells (63.6717.6%) were found to be CFSE
 and
had therefore proliferated extensively in the DLN (Fig. 2D and E).
In accordance with our previous studies, two distinct populations
of T cells, one of which that had undergone few divisions as well
as a population of CFSE
 T cells appeared in the CLN (Fig. 2E).
Interestingly, recipients of naı ¨ve BM3 T cells were found to
possess a higher percentage of CFSE
 cells in the CLN compared
to recipients of BM3 Tm (31.3713.5 versus 9.474.9%, respec-
tively), suggesting that CFSE
 effector T cells derived from a Tm
population had failed to undergo redistribution to the same
degree as those derived from naı ¨ve cells (Fig. 2E). Furthermore,
despite BM3 Tm undergoing similar levels of T-cell proliferation
to that of naı ¨ve BM3 T cells, the absolute number of BM3 T cells
present within the spleen, MLN, DLN and CLN of allograft reci-
pients at 10 days after transplantation was signiﬁcantly higher in
mice that had received naı ¨ve (39147713757cells) compared to
memory BM3 T cells (Fig. 2F, 1422274972 cells, po 0.05).
Similar allograft inﬁltration and pro-inﬂammatory
gene expression by BM3 Tm and naı ¨ve T cells
We next investigated whether Tm migrated more rapidly to the
allograft compared to naı ¨ve T cells, as an explanation for
accelerated graft rejection by Tm (Fig. 3). Using intra-graft CD3
mRNA expression (to quantitate graft inﬁltrating BM3 T cells; the
only T cells in these mice), we found that the level of CD3
Figure 1. CD8
1 BM3 Tm mediate accelerated rejection of H2K
b1 skin
grafts. 110
5 naı ¨ve (square) or memory BM3 (circle) T cells were
adoptively transferred to CBARAG
/ mice. One day later, mice
received an H2K
b1 skin graft and the kinetics of graft rejection
determined. p50.01 (Log-Rank test). n54 for Tm, n53 for naive. Data
are representative of ten independent experiments.
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expressed in untransplanted skin (data not shown) demonstrating
that no effector CD8
1 T cells, derived from either naı ¨ve or Tm, had
inﬁltrated grafts by 5 days post-transplantation (Fig. 3A). However,
by 10 days post transplantation, BM3 T cells in both sets of mice
had inﬁltrated the allografts, but no difference was found in the
extent of inﬁltration determined either by CD3 expression (Fig. 3B)
or by staining allografts with an anti-CD8 mAb (data not shown).
Similarly, gene expression analyses revealed no difference in the
intragraft expression of a number of pro-inﬂammatory genes such
as IFN-g, perforin, TNF-a, CCL4, CXCL10 and XCL1 between
allografts taken from mice that had received either Tm or naı ¨ve
BM3 T cells (Fig. 4B–D and G–I), although it was noted that mice
that had received Tm were found to express a twofold increase
in the levels of CCL5 and CXCL9 intragraft mRNA (Fig. 4E and F).
Intragraft expression of all genes was found to be signi-
ﬁcantly increased in all allografts compared to syngeneic grafts
(Fig. 4A–I).
Tm-mediated rapid rejection is dependent on
enhanced inﬁltration of skin allografts by PMN
As the studies had thus far failed to reveal any signiﬁcant
difference between the response of naı ¨ve and Tm to an
allograft, we next assessed the level of inﬁltration of
other cell types recruited to the skin allografts during
rejection to test the hypothesis that Tm may enable the
recruitment of other populations of effector cells that can
contribute to rejection. Skin allografts taken 10 days after
transplant from mice that had received BM3 Tm were found to
harbour an extensive PMN inﬁltrate, whereas PMN were rarely
found in the grafts of mice that had received naı ¨ve BM3 T cells
(Fig. 5).
To test whether inﬁltrating PMN contributed to accelerated
rejection, we investigated the impact of PMN depletion on allo-
graft rejection mediated by BM3 Tm (Fig. 6). Mice that received
BM3 Tm and a depleting anti-Gr-1 mAb on days 5, 10, 15 and 20
days i.p. post transplantation rejected skin allografts in a delayed
fashion compared to Tm-mediated rejection without anti-Gr-1
mAb (Fig. 6A; po 0.05), but with the same tempo as mice that had
received naı ¨ve BM3 T cells. As PMN repopulate rapidly after
depletion the experiment was repeated but the anti-Gr-1 mAb
was given every 3 days for 27 days. Again the accelerated rejec-
tion triggered by BM3 Tm was abrogated in mice treated with the
anti-Gr-1 mAb (Fig. 6B). Additionally, allografts transplanted to
mice that received naı ¨ve T cells and anti-Gr-1 mAb also enjoyed
prolonged survival (po0.05) with the grafts rejected with the
same kinetics as those placed on mice that received BM3 Tm and
anti-Gr-1 mAb.
Figure 2. Naı ¨ve and memory BM3 T cells undergo similar proliferation in the DLN following allogeneic skin transplantation 110
5 CFSE-labelled
naı ¨ve or memory BM3 T cells were adoptively transferred to CBARAG
/ mice. One day later, mice received an H2K
b1 skin graft. Five (A–C) or ten
(D–F) days following transplantation CD8
1Ti98
1TCR-b
1 (BM3) T cells in the CLN and DLN were analysed by ﬂow cytometry for CFSE ﬂuorescence
levels. (A) Representative CFSE versus CD8 dot-plots of live BM3 T cells in both CLN and DLN. Three mice/group. (B) Live BM3 T cells in the DLN of
mice that had received naı ¨ve or memory T cells and a skin allograft were split according to the number of times that they had divided (judged
according to CFSE dilution). Data show the mean percentage of BM3 T cells that had undergone a given division7SD by 5 days post
transplantation. (C) The percentage of live BM3 T cells (7SD) that had undergone 43 divisions in the CLN and DLN by 5 days post allogeneic skin
transplantation. Ten days post transplantation CFSE ﬂuorescence levels in CD8
1Ti98
1TCR-b
1 T cells in the (D) DLN and (E) CLN were used to
determine the % of BM3 T cells that had divided from 1 to 47 times. (F) The absolute number of CD8
1Ti98
1TCR-
1 T cells in pooled spleen,
mesenteric lymph node, CLN and DLN was determined using ﬂow cytometry. Data show mean7SD for three mice per group. p o 0.05; unpaired
Student’s t-test.
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Tm-mediated graft rejection
We have previously shown that whilst Treg can control graft
rejection mediated by naı ¨ve BM3 T cells, such cells are entirely
ineffective at controlling rejection by memory BM3 T cells [9].
We hypothesised that this failure to regulate Tm responses may
be due to the rapidity of rejection rather than an innate resistance
of Tm to regulation. To address this question, 110
5 memory
BM3 T cells were transferred to CBARAG
/ mice with or without
310
5 CD25
1CD4
1 T cells that had been isolated from
syngeneic mice that had received anti-CD4 and donor cells
(a protocol that we have previously shown to generate donor-
reactive Treg [16]). As previously demonstrated, such mice
rejected skin allografts acutely despite the co-injection of Treg
(Fig. 7). However, skin allografts transplanted to mice that had
received BM3 Tm, Treg and additionally were depleted of PMN
enjoyed prolonged survival with 65% of mice accepting the
allografts long-term (median survival time4100 days; n514;
Fig. 7A).
Analysis of such mice 100 days post transplantation revealed
that, as previously demonstrated following Treg suppression of
naı ¨ve BM3 T cells [9, 17], mice that received BM3 Tm, Treg and
PMN depletion had lower numbers of peripheral BM3 T cells than
in mice that did not receive Treg. Mice that had received
anti-Gr-1 mAb only had similar numbers of peripheral BM3
T cells to control mice (data not shown). Therefore, the extent of
loss of BM3 T cells was found to correlate with graft survival,
suggesting a common mechanism in the suppression of naı ¨ve and
Tm responses by donor-reactive Treg.
Discussion
Accumulating evidence suggests that Tm play an important, and
previously underestimated, role in allograft rejection. Further-
more, it has been suggested that the presence of Tm before
transplantation may form a barrier to the induction of tolerance
[10, 13, 18, 19]. Clearly, elucidation of the mechanisms by which
Tm mediate allograft rejection and resist the induction of
tolerance will be key to the translation of experimental tolerance
induction strategies to clinical transplantation as humans have
pre-existing Tm that recognise alloantigen either as a result of
heterologous immunity or sensitisation.
We have previously reported that CD8
1 BM3 Tm mediate
more rapid rejection than their naı ¨ve counterparts and are
resistant to suppression by Treg [9, 14]. We therefore postulated
that as an explanation for this phenomenon that Tm may show
enhanced proliferation, effector function and inﬁltration of skin
grafts after transplantation. It has previously been reported that
Tm have a lower activation threshold than naı ¨ve cells resulting in
the ability to respond to far lower doses of antigen [20–22] with a
reduced requirement for co-stimulation [23]. Following activa-
tion, it is also clear that Tm are capable of rapidly producing
effector cytokines [22, 24] and developing cytotoxicity following
restimulation [25]. Finally, Tm have been shown to express
differential adhesion molecules, lymphokine, chemokine and
chemokine receptors compared to naive T cells [26–30].
However, a comparison of the response of naı ¨ve and memory
CD8
1 T cells to a skin allograft in vivo, surprisingly failed to
identify any of these factors as being responsible for more rapid
skin allograft rejection mediated by CD8
1 Tm (Figs. 2–4).
In the light of these data, we propose that following allogeneic
skin transplantation, Langerhans cells activated by ischemia and
surgical trauma act as potent APC with full costimulatory capacity
nullifying the advantage Tm normally possess when responding to
antigen under conditions of suboptimal costimulation. In support of
this hypothesis, when we compared the ability of naı ¨ve and memory
BM3 T cells to respond to donor splenocytes in vivo,as i t u a t i o n
where alloantigen is encountered in the absence of inﬂammatory
stimuli and therefore limited costimulation, BM3 Tm proliferated
and expanded more rapidly than naı ¨ve BM3 T cells (threefold
greater expansion; data not shown). It should also be noted that it
takes 4–5 days for skin grafts to be re-vascularised which may delay
Tm entry into allografts and early expression of intragraft effector
Figure 3. Effector T cells derived from either naı ¨ve and memory BM3
T cells inﬁltrate skin allografts with the same kinetics. 110
5 CFSE-
labelled naı ¨ve or memory BM3 T cells were adoptively transferred to
CBARAG
/ mice. One day later, mice received an H2K
b1 skin graft.
Five (A) or ten (B) days following transplantation skin grafts were
evaluated for the expression of CD3 by quantitative RT-PCR as a surrogate
marker for BM3 T-cell inﬁltration. Data show mean CD3 mRNA (Units/
HPRT)7SD. N53s k i ng r a f t sa n a l y s e dper group per time-point.
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directly vascularised [31].
Despite the similar pattern of activation, proliferation and
graft inﬁltration of naı ¨ve and memory BM3 T cells in vivo,w e
clearly demonstrated that CD8
1 Tm rapidly recruit Gr-1
1 PMN
into rejecting allografts, an event that immediately precedes
rejection (Fig. 5). Furthermore, the depletion of Gr-1
1 cells from
the recipient was found to abrogate accelerated allograft rejec-
tion mediated by Tm (Fig. 6). Surprisingly, we found that Gr-1
1
cells were also utilised as an effector population involved in
rejection elicited by naı ¨ve CD8
1 T cells (Fig. 6 and data not
shown). Therefore, the difference in the kinetics of rejection
mediated by naı ¨ve or memory CD8
1 T cells appears to be a
quantitative, kinetic difference in the utilisation of PMN as
effector cells for rejection and not a qualitative difference.
The identiﬁcation that PMN play a critical role in accelerated
allograft rejection mediated by Tm raises the question as to how
Tm are able to stimulate migration of such cells to the graft site
more rapidly than naı ¨ve T cells. It has been shown that early
neutrophil inﬁltration directly relates to the number of antigen
primed CD8
1 T cells that subsequently enter the skin in response
to antigen challenge [32]. Such an interaction may occur through
the upregulation of CXCR1 by CD8
1 T cells [33]. However, in our
experiments neutrophil inﬁltration was observed a few days prior
to Tm-mediated rejection and did not correlate with increased
T-cell inﬁltration (Fig. 4A).
It is known that neutrophils may be recruited to tissues
expressing the chemokines CXCL1 and CXCL2, through expres-
sion of the chemokine receptor CXCR2 [34–37]. Indeed,
CXCR2
/ mice show reduced neutrophil inﬁltration and
expression of pro-inﬂammatory cytokines within transplanted
allografts [34]. As such, one possibility is that Tm are able to
induce expression of CXCL1 or CXCL2 at the graft site. In our
studies, we have found that intragraft expression of CXCL1 and
CXCL2 mRNA was increased, but that there was no signiﬁcant
difference between naı ¨ve and Tm-mediated rejection (data not
shown). It is also worth noting that BM3 Tm rapidly produce high
levels of IFN-g following reactivation and that IFN-g can mediate
Figure 4. CD8
1 T-cell inﬁltration and expression of effector, cytokine and chemokine genes during Tm and naı ¨ve BM3 T-cell-mediated rejection of
skin allografts 110
5 CFSE-labelled Tm (M) or naı ¨ve (N) BM3 T cells were adoptively transferred to CBARAG
/ mice. One day later, mice received
an allogeneic H2K
b1 (M1A and N1A) or syngeneic H2
k (M1S and N1S) skin graft. Ten days following transplantation, skin grafts were analysed for
the expression of pro-inﬂammatory mRNA. Data shown for mRNA expression (Units/HPRT) of (A) CD3, (B) IFN-g, (C) Perforin, (D) TNF-a, (E) CCL5,
(F) CXCL9, (G) CCL4, (H) CXCL10 and (I) XCL1. Data show three individual mice per group and the mean value (black dash). N/S5not signiﬁcant.
P values calculated using one-way ANOVA with Bonferroni post-test (multiple means).
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sion injury [38]. Therefore, we suggest that high-level peripheral
secretion of IFN-g together with the induction of intragraft
CXCL1/2 expression may be required to facilitate recruitment of
PMN to the graft.
Finally, we have previously shown that whilst alloreactive
Treg prevent rejection by naı ¨ve BM3 T cells, they are unable to
prevent BM3 Tm-mediated graft rejection [9]. We have also
shown that suppression of rejection elicited by naı ¨ve T cells in this
model was primarily due to the inﬁltration of skin allografts by
Treg and the deletion of intragraft effector T cells [17]. Based on
these observations, we proposed that the failure of Treg to control
Tm rejection may be due to the rapidity of rejection (through the
recruitment of PMN) preceding the establishment of intragraft
regulation. Here, we show that attenuating rapid Tm-mediated
rejection by the transient depletion of PMN was able to facilitate
the induction of long-term graft survival by Treg (Fig. 7). Indeed,
these data are consistent with that of El-Sawy et al. who showed
that transient PMN depletion resulted in long-term cardiac allo-
graft survival following costimulatory molecule blockade where
endogenous alloreactive CD8
1 Tm form a barrier to tolerance
induction in this model [39]. These data therefore suggest that
transient suppression of alloreactive Tm responses may enable
the generation of regulatory networks that maintain tolerance
even in the face of subsequent activation of alloreactive Tm.
Although in these studies Tm rejection was attenuated by
depletion of PMN, other approaches such as preferential Tm
depletion, blockade of certain costimulatory molecules or the
suppression of effector function (as shown for naı ¨ve T cells [40])
may also allow the induction of tolerance despite the presence of
alloreactive Tm.
In summary, we have performed a comparative study of the
mechanisms of allograft rejection utilised by BM3 CD8
1 Tm and
naı ¨ve T cells. We have demonstrated that PMN play an important
role in the rapid rejection of allografts elicited by memory
CD8
1 T cells. Furthermore, depletion of PMN was found to
attenuate allograft rejection mediated by BM3 Tm and allow
alloreactive Treg to maintain allograft survival long-term.
Materials and methods
Animals
CBA.Ca RAG-1 knockout (CBARAG
/) mice were a gift from Dr.
D. Kioussis (Mill Hill, London, UK). H2K
b-reactive TCR-trans-
genic mice (BM3; H2
k) were provided by Professor A. L. Mellor
(Institute of Molecular Medicine and Genetics, Augusta, GA, USA;
[41]). BM3RAG
/ were used in these studies. C57BL/6 (H2
b)
mice were originally purchased from Harlan Olac (Bicester, UK).
All mice were bred and housed in the BMS-JR, Oxford, in
accordance with the Animals (Scientiﬁc Procedure) Act 1986 of
the UK. All experiments used mice between ages 6 and 12 wk at
the time of ﬁrst procedure.
Figure 5. Tm-mediated rejection correlates with a diffuse inﬁltration
of PMN by 10 days post transplantation. 110
5 naı ¨ve or memory BM3
T cells were adoptively transferred to CBARAG
/ mice that received an
H2K
b1 skin graft 1 day later. Ten days following transplantation skin
grafts were analysed by immunohistochemistry for the presence of
PMN (using an anti-Gr-1 mAb). Photomicrographs are representative of
four sections per graft taken from three mice per group. Scale bars
represent approximately 50mM.
Figure 6. Accelerated rejection by BM3 Tm is prevented by the
administration of a depleting anti-Gr1 mAb. 110
5 naı ¨ve or memory
BM3 T cells were adoptively transferred to CBARAG
/ mice that
received an H2K
b1 skin graft 1 day later. Anti-Gr-1 mAb was
administered i.p. where indicated (200mg/dose) on days 5, 10, 15 and
20 post transplantation (A) or on days 3, 6, 9, 12, 15, 18, 21, 24 and 27
post transplantation (B). A comparison between groups labelled with
either  or  denotes a signiﬁcant difference between groups (p o 0.05;
Log-Rank test).
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Naı ¨ve BM3RAG
/ CD8
1 T cells
A single-cell leukocyte suspension was made from spleens
and mesenteric lymph nodes harvested from BM3RAG
/
TCR-transgenic mice. All CD8
1 T cells expressed the transgenic-
TCR identiﬁed using a mAb (Ti98). Cells were stained with anti-
CD8-APC and anti-CD44-PE mAb (both BD Biosciences,
Oxford, UK). Cells were used either unsorted (98% CD44
)o r
CD8
1CD44
 BM3 T cells were puriﬁed using a FACSAria
ﬂow cytometer. Typically preparations were 499% CD8
1
CD44
.
Memory BM3RAG
/ T cells
Leukocytes were prepared from CBARAG
/ mice that had received
110
5 BM3 T cells and C57BL/6 alloantigen (H2K
b1; skin allograft
or splenocyte injection) 50–100 days before harvest. Tm generated
by either method resulted in BM3 Tm that were phenotypically and
functionally identical. Cells were stained with anti-CD8-APC and
anti-CD44-PE mAb. Typically, cells contained 2–3% BM3 T cells, of
which490% were found to be CD44
1. BM3 Tm were used either
unsorted or CD44
1 BM3 T cells were puriﬁed using a FACSAria ﬂow
cytometer. Typically, cells were495% CD8
1CD44
1 T cells with
1–2% contamination with CD8
1CD44
 T cells.
CFSE labelling
Single-cell suspensions were incubated for 10min at 371C with
10mM CFSE (Molecular Probes), washed twice in ice-cold RPMI
1640 (Invitrogen Life Technologies), and resuspended in PBS
(Oxoid) ready for i.v. injection.
Skin transplantation
Individual full-thickness tail skin grafts were prepared to
ﬁt the graft bed on the left lateral thorax of anaesthetised
recipients. The grafts were inspected regularly until they were
completely destroyed, at which time the grafts were considered
rejected.
Flow cytometric analysis and mAb
Single-cell suspensions were prepared from spleen, MLN or
axillary lymph nodes. Cells were incubated with Fc block (BD
Biosciences) before being stained with anti-CD8-APC, anti-TCR-
b-PE (both BD Biosciences) and anti-transgenic-TCR (Ti98)-
biotin mAb. The Ti98-biotin mAb was developed using strepta-
vidin-CyChrome or streptavidin-APC-Cy7 (BD Biosciences). The
Ti98 hybridoma was a generous gift from Professor A. L. Mellor
[42]. All samples were then acquired immediately on either a
FACSort or FACSAria (BD Biosciences) and analysed using the
CellQuest or DIVA software package (BD Biosciences). Analysis of
the forward versus side scatter of a given sample enabled live cells
(and beads; see below) to be clearly distinguished from dead cells
and cell debris.
The depleting anti-Gr-1 mAb (RB6.8C5) was puriﬁed from a
hybridoma which was a kind gift from Professor Robert Fairchild
(Cleveland Clinic Foundation, Cleveland, OH, USA; [34]).
Enumeration of cell numbers by ﬂow cytometry
A ﬁxed number of 6mM synthetic ﬂuorescent beads (CaliBRITE
beads; BD Biosciences) were added to each sample. The ratio of
Figure 7. Treg suppress BM3 Tm-mediated rejection in the absence of
PMN 110
5 memory BM3 T cells were adoptively transferred alone or
together with CD25
1CD4
1 T cells isolated from syngeneic mice
that had received anti-CD4 mAb and donor cells to CBARAG
/ mice.
The following day, mice received an H2K
b1 skin graft and anti-Gr-1
mAb was administered i.p. where indicated (200mg/dose) on days 3, 6,
9, 12, 15, 18, 21, 24 and 27 post transplantation. (A) Skin allograft
survival; data pooled from two independent experiments. (B) Number
of spleen BM3 T cells at 100 days post transplantation. Data are
represented as the number of BM3 T cells in mice that received anti-
Gr-1 mAb and Treg as a percentage of BM3 T cells in mice that received
anti-Gr-1 mAb only. Mice that received anti-Gr-1 mAb and Treg were
split according to whether they had accepted skin allografts for 4100
days compared to those mice where skin allografts were ultimately
rejected.
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determined, from which the number of such cells per tube could
be calculated. The number of cells per tube was then multiplied
by the proportion of the sample placed into the FACS tube to
result in the total number of cells per sample/tissue [14].
Real-time PCR
Skin grafts were harvested, snap frozen and DNase I (Ambion)-
treated. Total RNA was isolated using the Absolutely RNA
Miniprep kit (Stratagene) and reversed transcribed by the
Moloney murine leukaemia virus reverse transcriptase (Invitro-
gen Life Technologies) as previously described [43]. An
additional DNase I digestion step was performed during reverse
transcription to ensure samples were free of genomic contamina-
tion. Real-time quantiﬁcation was performed using the ABI
PRISM 7700 Sequence Detection System (PE Applied Biosystems)
with either the ﬂuorogeneic probe (hypoxanthine phosphori-
bosyltransferase (HPRT), CD3, IFN-g, TNF-a and perforin) or the
SYBR Green technology (HPRT, CCL4, CCL5, XCL1, CXCL9 and
CXCL10). All samples were run in duplicate using the qPCR
Master Mix Plus (Eurogentec) or the Brilliant SYBR Green qPCR
Master Mix (Stratagene). All primers and probes for real-time
PCR have been previously described [14, 43]. Samples were
standardised for HPRT, and quantiﬁcation of the gene of
interest is given by 2
DCt, where DCt is obtained by calcu-
lating the difference between Ct of the gene of interest and
HPRT [44].
Immunohistochemistry
Thin frozen sections (7mm) were cut, air-dried overnight and
ﬁxed in acetone (BDH). After inhibition/blockade of endogenous
peroxidase activity and biotin, sections were incubated with anti-
Gr-1-biotin mAb (BD Biosciences) and the slides developed with
ABC complex (Vector Laboratories) and diaminobenzidine
substrate (Sigma-Aldrich). Sections were counterstained with
Gills haematoxylin (BDH) and mounted in DPX (BDH).
Statistical analysis
Statistical analysis was performed using Student’s t-test or one-
way ANOVA with Bonferroni post-test (multiple means). Graft
survival data were analysed by the log-rank test. Values for
po 0.05 were considered statistically signiﬁcant.
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